Our Services
Medical Information
Helpful Resources
Published on: 7/21/2026
Wegovy (semaglutide) typically lowers A1C by 1.0–1.5% over 6 to 9 months. Most patients see a 0.5–0.8% reduction by month 3, with maximum benefit reached by month 6. Individual results vary based on:
Several other factors can affect your personal timeline and treatment response.
Because A1C progress depends on so many individual variables — and because unmanaged blood sugar can lead to serious complications — it's worth understanding where you stand right now. A free, instant, online symptom check can help you evaluate your current symptoms, identify possible causes, and guide your next conversation with a healthcare provider. It takes just a few minutes and could help you take a more informed step toward better health.
Reviewed for medical accuracy: 07/21/2026
Doctor's Note: How Many Months Until Wegovy Drops Your A1C to Normal Range?
Managing type 2 diabetes often means keeping a close eye on your hemoglobin A1C (A1C)—the lab measure that reflects your average blood sugar over the past two to three months. Wegovy (semaglutide 2.4 mg weekly) is FDA-approved for chronic weight management but also shows promise in improving blood sugar control. Below, we'll review what you can realistically expect in terms of A1C reduction when you start Wegovy, month by month, based on clinical trial data and expert guidance.
Key Takeaways
Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist. In simple terms, it:
By attacking high blood sugar from several angles, Wegovy not only supports weight loss but also helps bring down your A1C.
Below is a general guide based on clinical trial averages (semaglutide 2.4 mg/weekly data adapted from obesity and diabetes studies). Your mileage may vary.
Month 1–2
Month 3
Month 4–6
Month 6–9
Beyond Month 9
Remember: never stop or change doses on your own. Always consult a healthcare professional for adjustments.
Experiencing unexpected symptoms while managing your diabetes? Try Ubie's free Medically approved LLM Symptom Checker Chat Bot to help you understand what's happening and determine if you need to contact your doctor right away.
Wegovy offers a powerful tool in the fight against high blood sugar, but it's not a standalone cure. Combine it with healthy habits, regular check-ups, and open communication with your healthcare team to reach—and maintain—a normal A1C.
Important Reminder: This information is for educational purposes only. Speak to your doctor or diabetes specialist about any symptoms that could be life-threatening or serious. Your medical team will tailor treatment to your unique needs and monitor you for safety and effectiveness.
(References)
* Davies M, et al. Once-weekly semaglutide 2·4 mg for the treatment of obesity in people with type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet. 2021 Jan 9;397(10271):132-144. doi: 10.1016/S0140-6736(20)32665-7. Epub 2020 Nov 18. PMID: 33211530.
* Wilding JPH, et al. Once-weekly semaglutide 2.4 mg for weight loss in adults with overweight or obesity: an international, multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2021 Feb 20;397(10271):119-131. doi: 10.1016/S0140-6736(20)32668-2. Epub 2020 Nov 18. PMID: 33211529.
* Kushner RF, et al. Long-term Efficacy and Safety of Once-Weekly Semaglutide for Weight Management in Adults With Overweight or Obesity (STEP 5). Diabetes Care. 2023 Mar 1;46(3):615-626. doi: 10.2337/dc22-1088. PMID: 36733276.
* Singh G, et al. Semaglutide 2.4 mg for the treatment of obesity: a review of current evidence. Diabetes Metab Syndr Obes. 2022 May 5;15:1289-1307. doi: 10.2147/DMSO.S329749. PMID: 35532599; PMCID: PMC9086435.
* O'Neil PM, et al. Once-weekly semaglutide 2.4 mg for the treatment of obesity: a systematic review and meta-analysis of the STEP program. Obes Rev. 2022 Apr;23(4):e13381. doi: 10.1111/obr.13381. Epub 2022 Feb 16. PMID: 35166468; PMCID: PMC9292945.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.